Quantitative evaluation of the genus Bifidobacterium in stool samples of patients with type 1 and 2 diabetes DOI Open Access
Agnieszka Krawczyk, Katarzyna Talaga-Ćwiertnia, Katarzyna Biegun

et al.

Postępy Higieny i Medycyny Doświadczalnej, Journal Year: 2023, Volume and Issue: 77(1), P. 59 - 64

Published: Jan. 1, 2023

Abstract Introduction There is evidence of the existence quantitative changes in microbiome, including Bifidobacterium spp., due to some chronic diseases, such as liver cirrhosis, inflammatory bowel obesity, or celiac disease. Materials and Methods We aimed examine number total bacteria present colon patients with type 1 diabetes (T1DM) 2 (T2DM), well healthy subjects. DNA was extracted from patients’ fecal samples then amplified by real-time PCR determine bacteria. Statistical association selected clinical biochemical features examined. Results The mean numbers belonging genus T1DM T2DM were lower compared control group (p = 0.006, p < 0.001 respectively). no statistical differences between all groups 0.397). In group, a significant correlation detected bifidobacteria age (r 0.441, 0.010), alanine aminotransferease 0.022, r −0.11). T2DM, observed triglycerydes 0.001, −0.61). Moreover, we have found negative HBA1, glucose level, −0.35, −0.024, 0.019, Conclusions composition controls. Further studies are needed clarify relationship these elements picture T1DM.

Language: Английский

CGA protects against experimental colitis by modulating host purine metabolism through the gut microbiota DOI
Xiaolin Ye,

Xueying An,

Tianzhuo Zhang

et al.

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 153, P. 114547 - 114547

Published: March 27, 2025

Language: Английский

Citations

1
The Impact of a Very-Low-Calorie Ketogenic Diet in the Gut Microbiota Composition in Obesity DOI Open Access
Ana Karina Zambrano, Santiago Cadena-Ullauri, Patricia Guevara-Ramí­rez

et al.

Nutrients, Journal Year: 2023, Volume and Issue: 15(12), P. 2728 - 2728

Published: June 13, 2023

The very-low-calorie KD (VLCKD) is characterized by a caloric intake of under 800 kcal/day divided into less than 50 g/day carbohydrate (13%) and 1 to 1.5 g protein/kg body weight (44%) 43% fat. This low changes the energy source from glucose ketone bodies. Moreover, clinical trials have consistently shown beneficial effect VLCKD in several diseases, such as heart failure, schizophrenia, multiple sclerosis, Parkinson’s, obesity, among others. gut microbiota has been associated with metabolic conditions person regulated diet interactions; furthermore, it that role homeostasis regulating metabolism, appetite, energy. Currently, there increasing evidence an association between dysbiosis pathophysiology obesity. In addition, molecular pathways, metabolites, how modulation could be remain unclear, more research needed. objective present article contribute overview impact on intestinal composition individuals obesity through literature review describing latest regarding topic highlighting which bacteria phyla are VLCKD.

Language: Английский

Citations

20
Mechanisms of epigallocatechin gallate (EGCG) in ameliorating hyperuricemia: insights into gut microbiota and intestinal function in a mouse model DOI

Haonan Yu,

Zhenyou Lou,

Tingbo Wu

et al.

Food & Function, Journal Year: 2024, Volume and Issue: 15(11), P. 6068 - 6081

Published: Jan. 1, 2024

Epigallocatechin gallate (EGCG), a prominent bioactive compound found in tea, offers numerous health benefits. Previous studies have highlighted its potential mitigating hyperuricemia. In this study, hyperuricemic mice induced by potassium oxonate (PO) were treated with EGCG or the anti-hyperuricemia medication allopurinol (AP) to investigate mechanisms underlying their anti-hyperuricemic effects. The results demonstrated that both and AP significantly reduced serum uric acid (UA) levels. Further analysis revealed promoted expression of UA secretion transporter genes (

Language: Английский

Citations

8
Gut microecology: effective targets for natural products to modulate uric acid metabolism DOI Creative Commons
Hui Wang,

Yixuan Zheng,

Mengfan Yang

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Aug. 28, 2024

Gut microecology,the complex community consisting of microorganisms and their microenvironments in the gastrointestinal tract, plays a vital role maintaining overall health regulating various physiological pathological processes. Recent studies have highlighted significant impact gut microecology on regulation uric acid metabolism. Natural products, including monomers, extracts, traditional Chinese medicine formulations derived from natural sources such as plants, animals, microorganisms, also been investigated for potential modulating According to research, The stability is crucial link products maintain healthy metabolism reduce hyperuricemia-related diseases. Herein, we review recent advanced evidence revealing bidirectional between And separately summarize key extracts herbal both aspects. In addition,we elucidated important mechanisms secondary diseases through microecology, especially by composition microbiota, mucosal barrier, inflammatory response, purine catalyzation, associated transporters. This may offer novel insight into its disorders management highlight perspective exploring therapeutic drugs products.

Language: Английский

Citations

7
Study on the mechanism of Orthosiphon aristatus (Blume) Miq. in the treatment of hyperuricemia by microbiome combined with metabonomics DOI Open Access
Chunsheng Zhu, Hongjuan Niu, Meng Bian

et al.

Journal of Ethnopharmacology, Journal Year: 2023, Volume and Issue: 317, P. 116805 - 116805

Published: June 23, 2023

Language: Английский

Citations

16
Lactobacillus gasseri LG08 and Leuconostoc mesenteroides LM58 exert preventive effect on the development of hyperuricemia by repairing antioxidant system and intestinal flora balance DOI Creative Commons

Lizhen Liang,

Zihui Meng, Fei Zhang

et al.

Frontiers in Microbiology, Journal Year: 2023, Volume and Issue: 14

Published: June 12, 2023

Currently, hyperuricemia has shown a surprisingly rising trend, which attracts widespread attention due to potentially major health risks. Considering the inevitable side effects of long-term medicine, probiotics are emerging as potential therapeutics their ability improve uric acid metabolism and superior safety.In our study, two strains probiotics, Lactobacillus gasseri LG08 (LG08) Leuconostoc mesenteroides LM58 (LM58) isolated from kimchi were evaluated for prebiotic properties in vitro uric-lowering vivo. Here, animal model 16S rRNA gene amplicons analysis further studied investigate whether these exert different prevention treatment.In vivo indicators intestinal flora immunity revealed that both significantly prevent development progression hyperuricemia, repair antioxidant system maintain balance healthy rats, especially LM58. After was formed, although effect could decrease level acid, reverse levels body limited.In findings have important implications therapy, provided more mechanistic insights into hyperuricemia.

Language: Английский

Citations

13
Gut Microbiome and Metabolome Alterations in Overweight or Obese Adult Population after Weight-Loss Bifidobacterium breve BBr60 Intervention: A Randomized Controlled Trial DOI Open Access
Zhouya Bai, Ying Wu,

Dejiao Gao

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 10871 - 10871

Published: Oct. 10, 2024

Probiotics, known for regulating gut microbiota, may aid those with overweight or obesity, but their mechanisms require more research. This study involved 75 obese young adults, randomly assigned to either a

Language: Английский

Citations

4
Lactobacillus paracasei L9 ameliorated obesity-associated metabolic parameters and relevant gut microbiota in mice fed a high-fat diet DOI
Nan Sun,

Shanbin Chen,

Yixuan Li

et al.

Nutrition Research, Journal Year: 2023, Volume and Issue: 115, P. 26 - 37

Published: April 29, 2023

Language: Английский

Citations

11
Alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia DOI Creative Commons
Ping Liu,

Jianli Yang,

Yu Chen

et al.

Heliyon, Journal Year: 2023, Volume and Issue: 9(9), P. e20328 - e20328

Published: Sept. 1, 2023

ObjectThis study aims to investigate the changes in gut microbiota and metabolism of patients with chronic kidney disease (CKD) stage 1–2, as well potential impact hyperuricemia (HUA) on these factors CKD 1–2 patients.MethodsIn this study, fecal samples were collected from without HUA (CKD-N group), (CKD-H healthy people controls (HCs group). The then subjected microbiome (16S rRNA gene sequencing) metabolome (liquid chromatography-tandem mass spectrometry) analyses. multi-omics datasets analyzed individually integrated for combined analysis using various bioinformatics approaches.ResultsGut microbial dysbiosis was found CKD-N CKD-H patients. At phylum level, compared HCs group, Bacteroidetes decreased but Proteobacteria increased group significantly. Fusobacteria significantly lower than group. genus [Eubacterium]_ventriosum_group, Fusobacterium, Agathobacter, Parabacteroides, Roseburia changed groups. [Ruminococcus]_gnavus_group Moreover, altered d-glutamine d-glutamate metabolism, arginine proline histidine lysine biosynthesis down-regulated Phenylalanine purine beta-alanine up-regulated There a significant difference between two groups phenylalanine metabolism. abundance change [Ruminococcus]_gnavus_group, UCG-002, Alistipes, Bifidobacterium had close correlation differential metabolites.ConclusionThe metabolic status undergo people. Additionally, has been patients, their association metabolites suggests that former plays crucial role

Language: Английский

Citations

11
Role of human milk oligosaccharide metabolizing bacteria in the development of atopic dermatitis/eczema DOI Creative Commons

Trisha Rahman,

Prioty F. Sarwar,

Cassandra C. Potter

et al.

Frontiers in Pediatrics, Journal Year: 2023, Volume and Issue: 11

Published: March 20, 2023

Despite affecting up to 20% of infants in the United States, there is no cure for atopic dermatitis (AD), also known as eczema. Atopy usually manifests during first six months an infant's life and one predictor later allergic health problems. A diet human milk may offer protection against developing dermatitis. One component, oligosaccharides (HMOs), plays important role a prebiotic establishing infant gut microbiome has immunomodulatory effects on immune system. The purpose this review summarize available information about bacterial members intestinal microbiota capable metabolizing HMOs, genes or metabolic products present tract early life, relationship these development AD/eczema infants. We find that specific HMO metabolism gene sets metabolites produced by bacteria enable protective atopy because interactions with identify areas additional research further elucidate between atopy. Detailed metagenomic studies its associated metabolomes are essential characterizing potential impact milk-feeding

Language: Английский

Citations

10